Brink Therapeutics focuses on developing innovative therapies that harness the power of the immune system to treat various diseases, particularly cancer. The company employs a proprietary platform that integrates advanced technologies to identify and optimize therapeutic candidates. This platform is designed to enhance the efficacy and safety of treatments by leveraging insights from immunology and molecular biology, allowing for the creation of targeted therapies that can effectively engage the immune response against tumors.

In addition to its therapeutic pipeline, Brink Therapeutics emphasizes the importance of collaboration and scientific rigor in its research efforts. The company utilizes cutting-edge techniques such as high-throughput screening and bioinformatics to streamline the drug discovery process. By combining these technologies with a deep understanding of disease mechanisms, Brink aims to accelerate the development of novel immunotherapies that can improve patient outcomes and address unmet medical needs in oncology.

France

Brink Therapeutics is developing next-generation recombinases — ultra-precise and efficient enzymes that surpass CRISPR-Cas9. We aim to revolutionize Cell and Gene therapies, enabling large-scale production to treat cancer, genetic disorders, and other diseases.

Brink Therapeutics

Company Details